Miyazaki, T., Hirokami, Y., Matsuhashi, N., Takatsuka, H
However, strange as it may seem knowing what we know now, commercialisation was slow
According to the International Foundation of Employee Benefit Plans, as of 2025: 55% of employers cover GLP-1 medications only for diabetes through their health plans, down from 57%in 2024 36% cover GLP-1 medications for both diabetes and weight loss through their health plans, up from 34%in 2024 Other sources report a much higher GLP-1 coverage for weight loss, between 49% and 57% among employers
The manufacturer has already developed a new patch-type diabetes treatment (egg microneedle) to overcome the limitations of existing dissolvable microneedles, exhibiting potential for successful GLP-1 patch development